Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Prothena Corporation plc (NASDAQ: PRTA) announced that the U.S. Food and Drug Administration (FDA) has...
Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors – Novel Bispecific Fc Fusion Protein Targets “Cold Tumors”
Jecho Biopharmaceuticals Co., Ltd., a China-based joint venture between U.S.-based Jecho Laboratories, Inc. and France-headquartered...
Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced this week that Botox has received marketing...
Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
Huahui Health, a Beijing-based biotechnology company focused on viral hepatitis, hepatology, and oncology, announced a...
WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
WuXi AppTec Co., Ltd. (SHA: 603259; HKG: 2359), China’s leading integrated Contract Research Organization (CRO),...
Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
Thermo Fisher Scientific Inc. (NYSE: TMO) announced on April 27, 2026, that it has signed...
Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
Novartis AG (NYSE: NVS) announced on April 27, 2026, that the European Commission (EC) has...
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on...
Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design
Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of its Series...
BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced it has received approval from the...
Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China
Hinova Pharmaceuticals Inc. (SHA: 688302) announced positive interim results from its Phase IIa clinical study...
Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry
Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues...
Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
Adcoris, a Hangzhou-based bioconjugation specialist, announced a global licensing agreement with U.S.-headquartered K2 Therapeutics, Inc....
Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
Chia Tai Tianqing Pharmaceutical Group, a wholly owned subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177),...
Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
Novartis AG (NYSE: NVS) announced that the Committee for Medicinal Products for Human Use (CHMP)...
Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the Center for Drug Evaluation (CDE)...
Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Brii Biosciences (HKG: 2137) unveiled a cross-study pooled analysis of hepatitis B surface antigen (HBsAg)...
CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration (FDA)...
Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) announced a landmark collaboration with Mark Cuban...
Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced regulatory clearance from Australia’s Therapeutic Goods Administration (TGA)...